The results of the phases 1 and 2 of the clinical trials showed 93.5% (95% CI, 88.4–99.6%) of the receivers of the vaccine have produced neutralizing antibodies against SARS-CoV-2.[6] Those results have not been peer-reviewed yet. Officials in charge say they are in the process to publish them in a peer-reviewed journal.[2]